These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 24831086)

  • 1. Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers.
    Sun CK; Zhang F; Xiang T; Chen Q; Pandita TK; Huang Y; Hu MC; Yang Q
    Oncotarget; 2014 May; 5(10):3375-85. PubMed ID: 24831086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
    Hong R; Ma F; Zhang W; Yu X; Li Q; Luo Y; Zhu C; Jiang W; Xu B
    BMC Cancer; 2016 Sep; 16(1):725. PubMed ID: 27613518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.
    Jaspers JE; Kersbergen A; Boon U; Sol W; van Deemter L; Zander SA; Drost R; Wientjens E; Ji J; Aly A; Doroshow JH; Cranston A; Martin NM; Lau A; O'Connor MJ; Ganesan S; Borst P; Jonkers J; Rottenberg S
    Cancer Discov; 2013 Jan; 3(1):68-81. PubMed ID: 23103855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.
    Henneman L; van Miltenburg MH; Michalak EM; Braumuller TM; Jaspers JE; Drenth AP; de Korte-Grimmerink R; Gogola E; Szuhai K; Schlicker A; Bin Ali R; Pritchard C; Huijbers IJ; Berns A; Rottenberg S; Jonkers J
    Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8409-14. PubMed ID: 26100884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.
    Sun Y; Gallacchi D; Zhang EY; Reynolds SB; Robinson L; Malinowska IA; Chiou TT; Pereira AM; Li C; Kwiatkowski DJ; Lee PS; Yu JJ
    Am J Respir Cell Mol Biol; 2014 Dec; 51(6):738-49. PubMed ID: 24874429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
    Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
    Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA-PK inhibitor AZD7648 is a more portent radiosensitizer than PARP inhibitor Olaparib in BRCA1/2 deficient tumors.
    Wang T; Kyle AH; Baker JHE; Liu NA; Banáth JP; Teymori S; Minchinton AI
    DNA Repair (Amst); 2024 Jul; 139():103689. PubMed ID: 38749239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cationic liposome codelivering PI3K pathway regulator improves the response of BRCA1-deficient breast cancer cells to PARP1 inhibition.
    Zhang H; Yu N; Chen Y; Yan K; Wang X
    J Cell Biochem; 2019 Aug; 120(8):13037-13045. PubMed ID: 30873673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folliculin deficient renal cancer cells exhibit BRCA1 A complex expression impairment and sensitivity to PARP1 inhibitor olaparib.
    Zhang Q; Xu Y; Zhang Z; Li J; Xia Q; Chen Y
    Gene; 2021 Feb; 769():145243. PubMed ID: 33069804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer.
    Paul I; Savage KI; Blayney JK; Lamers E; Gately K; Kerr K; Sheaff M; Arthur K; Richard DJ; Hamilton PW; James JA; O'Byrne KJ; Harkin DP; Quinn JE; Fennell DA
    J Pathol; 2011 Aug; 224(4):564-74. PubMed ID: 21706479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
    Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
    Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.
    van de Ven M; van der Burg E; van der Gulden H; Klarenbeek S; Bouwman P; Jonkers J
    J Pathol; 2017 Mar; 241(4):511-521. PubMed ID: 27943283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors.
    Yang ZM; Liao XM; Chen Y; Shen YY; Yang XY; Su Y; Sun YM; Gao YL; Ding J; Zhang A; He JX; Miao ZH
    Acta Pharmacol Sin; 2017 Jul; 38(7):1038-1047. PubMed ID: 28414200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells.
    Węsierska-Gądek J; Zulehner N; Ferk F; Składanowski A; Komina O; Maurer M
    Biochem Pharmacol; 2012 Nov; 84(10):1318-31. PubMed ID: 22906755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers.
    Lei G; Mao C; Horbath AD; Yan Y; Cai S; Yao J; Jiang Y; Sun M; Liu X; Cheng J; Xu Z; Lee H; Li Q; Lu Z; Zhuang L; Chen MK; Alapati A; Yap TA; Hung MC; You MJ; Piwnica-Worms H; Gan B
    Cancer Discov; 2024 Aug; 14(8):1476-1495. PubMed ID: 38552003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells.
    Chuang HC; Kapuriya N; Kulp SK; Chen CS; Shapiro CL
    Breast Cancer Res Treat; 2012 Jul; 134(2):649-59. PubMed ID: 22678161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
    J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas.
    Bi Y; Verginadis II; Dey S; Lin L; Guo L; Zheng Y; Koumenis C
    Gynecol Oncol; 2018 Sep; 150(3):534-544. PubMed ID: 30025822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.